The names on this page are hidden. Create a free account to reveal 5 records a month, or get Private Equity Intelligence at $249 a month for every name. Every figure, date and source on this page is public either way.

Transactions / L••• G••••

SK Capital Completes Acquisition of L••• G••••’s Medical Division and Launches New Platform as Precera Medical

Platform acquisitionclosedannounced Nov 3, 2025closed Nov 3, 2025Fact
What happened
Platform
not an add-on on record
Control
Control
Share acquired
unknown
Industry
industrials / components, industrial, manufactur
Target location
unknown
Seller kind
unknown
Rollover
unknown
Values, only where disclosed
Enterprise value
Not disclosed
Purchase price
Not disclosed
Equity value
Not disclosed
Target revenue
Not disclosed
Target EBITDA
Not disclosed
Multiple
Not disclosed
Parties and roles
7 named
Buy side
  • S• C•••••• P•••••••, LP (“SK Capital”), a New York-based private investment firm focused on the specialty materials, ingredients, and life sciences sectors, has completed the previously announced acquisition of L••• G••••’s (Euronext: FII) Medical division (the “Transaction”).
Financing side
Advisory side
  • S••••••• C•••••••• F••••••Buy-side adviserconfirmed
    Piper Sandler & Co., Jefferies LLC, and S••••••• C•••••••• F•••••• served as financial advisors and K••••••• • E•••• served as legal counsel to SK Capital.
  • K••••••• • E•••• L••Legal adviserconfirmed
    Piper Sandler & Co., Jefferies LLC, and S••••••• C•••••••• F•••••• served as financial advisors and K••••••• • E•••• served as legal counsel to SK Capital.
  • D••••••Legal adviserconfirmed
    Rothschild & Co served as financial advisor and D•••••• served as legal counsel to L••• G••••.
  • F••• A•••••Sell-side adviserconfirmed
    Rothschild & Co served as financial advisor and D•••••• served as legal counsel to L••• G••••.
Side not stated
  • S• C•••••• P•••••••, LP (“SK Capital”), a New York-based private investment firm focused on the specialty materials, ingredients, and life sciences sectors, has completed the previously announced acquisition of L••• G••••’s (Euronext: FII) Medical division (the “Transaction”).
Evidence
S• C•••••• P•••••••, LP (“SK Capital”), a New York-based private investment firm focused on the specialty materials, ingredients, and life sciences sectors, has completed the previously announced acquisition of L••• G••••’s (Euronext: FII) Medical division (the “Transaction”).
SK Capital Completes Acquisition of L••• G••••’s Medical Division and Launches New Platfor | Private Equity Intelligence | DFX